What Happened
- A bench of the Supreme Court of India, comprising the Chief Justice and Justice Joymalya Bagchi, agreed to examine the feasibility of mandatory Nucleic Acid Testing (NAT) for blood transfusion safety across all blood banks in the country.
- The case arose from a Public Interest Litigation (PIL) filed by Delhi-based NGO Sarvesham Mangalam Foundation, which sought directions to make NAT compulsory at all blood banks.
- The petition was prompted by incidents in 2025 where children with Thalassemia were reportedly infected with HIV after receiving blood transfusions at government hospitals in Madhya Pradesh (Satna) and Jharkhand (Chaibasa).
- While the bench acknowledged the importance of the issue, it also expressed caution about courts directing highly technical medical decisions — noting that such matters fall within the domain of medical experts and state health secretaries.
- The court directed the petitioner to submit a detailed representation before health secretaries of all States and Union Territories, who can examine the matter with medical expert inputs.
Static Topic Bridges
Nucleic Acid Testing (NAT): Science and Blood Safety Significance
Nucleic Acid Testing (NAT) is a molecular diagnostic technique that detects the genetic material — DNA or RNA — of pathogens (viruses and bacteria) directly in donated blood, rather than detecting antibodies produced in response to infection. The critical advantage of NAT over conventional serological tests (such as ELISA — Enzyme-Linked Immunosorbent Assay) lies in its ability to dramatically shorten the "window period" — the interval between infection and detectability. For HIV, conventional ELISA tests have a window period of approximately 14–45 days; NAT reduces this to just 5–11 days.
- NAT detects pathogen nucleic acid (RNA/DNA) — active infection, not antibody response
- Window period reduction: HIV window period (ELISA: 14–45 days) → NAT: 5–11 days
- NAT also detects Hepatitis B (HBV), Hepatitis C (HCV), and other pathogens with reduced window periods
- Indian blood banks currently screen for 5 Transfusion Transmitted Infections (TTIs): HIV, HBV, HCV, Malaria, Syphilis
- Serological screening (ELISA) is standard at most blood banks; NAT remains available at select centres
- NAT is more expensive and requires specialised infrastructure — a key barrier to universal rollout in India
- NAT can be performed as individual donation NAT (ID-NAT) or mini-pool NAT (MP-NAT); ID-NAT is more sensitive
Connection to this news: The Supreme Court case centres on whether NAT's superior sensitivity — particularly its shorter window period — justifies mandatory rollout at all blood banks to prevent transfusion-transmitted infections, especially in multi-transfused patients like those with Thalassemia.
Blood Safety Regulation in India: NBTC, NACO, and Drugs and Cosmetics Act
Blood transfusion safety in India is governed by a multi-institutional framework. The National Blood Transfusion Council (NBTC), functioning under the National AIDS Control Organisation (NACO) within the Ministry of Health and Family Welfare, is the apex policy body for blood and blood component-related issues. Operationally, blood banks are licensed and regulated under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, which specify mandatory testing requirements, storage conditions, and quality standards for blood banks.
- NBTC: apex policy-making body for blood; functions under NACO/MoHFW
- NACO: operational since 1992; oversees National AIDS Control Programme; coordinates blood safety
- Regulation: blood banks licensed under Drugs and Cosmetics Act, 1940; Schedule F Part XII covers blood banking standards
- Mandatory TTI screening: HIV 1&2, HBV, HCV, Malaria, Syphilis — all donated blood units
- NACO data: transfusion-transmitted HIV infections — approximately 1,342 cases in 2018-19
- India's transfusion-transmitted HIV has declined from 8–10% of total HIV cases (two decades ago) to under 1% currently
- Voluntary blood donation: government policy prioritises voluntary (over replacement/paid) donors for safety
Connection to this news: The Supreme Court's examination of NAT feasibility essentially asks whether NBTC and MoHFW should be directed to upgrade the mandatory screening standard in the Drugs and Cosmetics Rules — a question that sits at the intersection of judicial oversight and technical health policy.
PIL Jurisdiction and Judicial Restraint in Technical Policy Matters
The Supreme Court's approach in this case — acknowledging the issue while directing the petitioner to the executive rather than issuing immediate directions — reflects the doctrine of judicial restraint in matters requiring technical expertise. The Supreme Court and High Courts exercise Public Interest Litigation (PIL) jurisdiction to enforce fundamental rights and ensure state compliance with constitutional obligations, including the right to health under Article 21. However, courts have consistently held that policy decisions requiring expert assessment — on medical standards, economic choices, or technical regulations — should remain primarily with the executive and legislature, subject to judicial review only on grounds of arbitrariness, irrationality, or fundamental rights violations.
- PIL: procedural flexibility allowing any public-spirited person to approach courts on behalf of affected groups
- Article 21: right to life includes the right to health (affirmed in Paschim Banga Khet Mazdoor Samity v. State of West Bengal and subsequent judgements)
- Judicial restraint doctrine: courts should not substitute their judgement for that of technical experts in specialised fields (see Vellore Citizens' Welfare Forum, Aruna Shanbaug cases for limits)
- State health secretaries: the court directed representations to them — channelling the issue through the executive rather than bypassing it
- PIL abuse concerns: Supreme Court has periodically flagged misuse of PIL for private gains or publicity
Connection to this news: The bench's caution about courts pretending to "know medical science" directly invokes the doctrine of judicial restraint — signalling that while the court is seized of the issue, it will require expert-backed evidence from state governments before directing a mandatory policy change.
Key Facts & Data
- NAT window period (HIV): 5–11 days vs. ELISA: 14–45 days
- 5 mandatory TTI screens at Indian blood banks: HIV, HBV, HCV, Malaria, Syphilis
- Transfusion-transmitted HIV in India: ~1,342 cases (2018-19); down from 8–10% of total HIV cases to under 1% currently
- Madhya Pradesh (Satna), 2025: at least 6 Thalassemia children tested HIV-positive post-transfusion
- Jharkhand (Chaibasa), 2025: 5 children reportedly infected via blood transfusion
- PIL filed by: Sarvesham Mangalam Foundation (Delhi-based NGO)
- Court bench: Chief Justice Surya Kant and Justice Joymalya Bagchi
- Court direction: submit representation to health secretaries of all States/UTs